Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.

Prostate Cancer and Prostatic Diseases
G PloussardA de la Taille

Abstract

Therapeutic strategy remains unclear with no clear consensus for men with high-risk prostate cancer (PCa) after radical prostatectomy. We aimed to evaluate into a prospective randomized trial the effectiveness and feasibility of adjuvant weekly paclitaxel combined with androgen deprivation therapy (ADT) in these patients. A total of 47 patients with high-risk PCa were randomized 6 weeks after radical prostatectomy: ADT alone versus combination of ADT and weekly paclitaxel. Toxicity, quality-of-life and functional results were compared between the two arms. All 23 patients completed eight cycles of paclitaxel. Toxicity was predominantly of grade 1-2 severity. There were no differences in EORTC QLQ-C30 scores between the two groups and between baseline and last assessment at 24 months after surgery. Urinary continence was complete at 1 year after surgery for all patients and no significant differences were noted at each assessment between the two groups. The interim analysis of this trial confirms the feasibility of weekly paclitaxel in combination with ADT in men at high-risk PCa with curative intent. This adjuvant combined therapy does not alter quality-of-life and continence recovery after surgery plus ADT. A larger cohort is ...Continue Reading

References

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W KattanP T Scardino
Aug 13, 2003·The Journal of Urology·L H KlotzUNKNOWN Canadian Uro-Oncology Group
Dec 4, 2003·European Urology·Laurent SalomonClément-Claude Abbou
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phillip G FebboWilliam K Oh
Jan 25, 2006·BJU International·David G McLeodUNKNOWN Casodex Early Prostate Cancer Trialists' Group
Jun 6, 2006·The Lancet Oncology·Edward M MessingUNKNOWN Eastern Cooperative Oncology Group study EST 3886
Nov 16, 2006·JAMA : the Journal of the American Medical Association·Ian M ThompsonE David Crawford
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

May 11, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Lígia C Gomes-da-SilvaJoão N Moreira
Feb 9, 2012·Current Urology Reports·Alexandre IngelsGuillaume Ploussard
Jun 1, 2012·Expert Opinion on Pharmacotherapy·Stavros Sfoungaristos, Petros Perimenis
Nov 6, 2013·Hematology/oncology Clinics of North America·Elaine T Lam, L Michael Glodé
Nov 2, 2015·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·M Soulié, L Salomon
Aug 12, 2014·European Urology·Giorgio GandagliaMaxine Sun
Oct 13, 2018·Urologic Oncology·Matthew J FerrisAshesh B Jani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.